Literature DB >> 3488908

Lysis of bystander target cells after triggering of human cytotoxic T lymphocytes.

B Fleischer.   

Abstract

Human cloned cytotoxic T lymphocytes (CTL) specific for class I HLA antigens were used to investigate whether triggering of CTL leads to killing of innocent bystander target cells. After triggering of CTL by their specific target cells, lysis of bystander targets was detected in a 7-h cytotoxicity assay. Considerable differences were found in the susceptibility of various target cells to this type of lysis. Targets susceptible to this bystander lysis were also susceptible to lysis by CTL triggered by F(ab')2 fragments of an anti-T3 monoclonal antibody, whereas other targets were resistant to both types of cytotoxicity. Triggering of CTL by oxidized target cells or via a T3-independent activation pathway led to bystander lysis detectable already after 4 h. Bystander lysis was considerably enhanced under conditions that facilitated a non-specific cell contact between CTL and bystander target. We conclude that a function besides antigen recognition of the T cell receptor on CTL is to direct killing to the target cell. This directing, however, is incomplete and destruction of innocent bystanders can be detected under appropriate conditions.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3488908     DOI: 10.1002/eji.1830160826

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  Clonal analysis of liver-derived T cells of patients with primary biliary cirrhosis.

Authors:  R M Hoffmann; G R Pape; U Spengler; E P Rieber; J Eisenburg; J Döhrmann; G Paumgartner; G Riethmüller
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

2.  CD8+ T lymphocytes of patients with AIDS maintain normal broad cytolytic function despite the loss of human immunodeficiency virus-specific cytotoxicity.

Authors:  G Pantaleo; A De Maria; S Koenig; L Butini; B Moss; M Baseler; H C Lane; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

3.  WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy.

Authors:  Lillian Sun; Ellen Moore; Rose Berman; Paul E Clavijo; Anthony Saleh; Zhong Chen; Carter Van Waes; John Davies; Jay Friedman; Clint T Allen
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

4.  Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan.

Authors:  E Barker; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

5.  A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy.

Authors:  Ranjan Upadhyay; Jonathan A Boiarsky; Gvantsa Pantsulaia; Judit Svensson-Arvelund; Matthew J Lin; Aleksandra Wroblewska; Sherry Bhalla; Nathalie Scholler; Adrian Bot; John M Rossi; Norah Sadek; Samir Parekh; Alessandro Lagana; Alessia Baccarini; Miriam Merad; Brian D Brown; Joshua D Brody
Journal:  Cancer Discov       Date:  2020-12-17       Impact factor: 39.397

6.  Self recognition by T cells. I. Bystander killing of target cells bearing syngeneic MHC antigens.

Authors:  R C Duke
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

7.  A monoclonal antibody specific for a common determinant of the human T cell receptor gamma/delta directly activates CD3+WT31- lymphocytes to express their functional program(s).

Authors:  E Ciccone; S Ferrini; C Bottino; O Viale; I Prigione; G Pantaleo; G Tambussi; A Moretta; L Moretta
Journal:  J Exp Med       Date:  1988-07-01       Impact factor: 14.307

8.  Two subsets of human T lymphocytes expressing gamma/delta antigen receptor are identifiable by monoclonal antibodies directed to two distinct molecular forms of the receptor.

Authors:  C Bottino; G Tambussi; S Ferrini; E Ciccone; P Varese; M C Mingari; L Moretta; A Moretta
Journal:  J Exp Med       Date:  1988-08-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.